Market Cap
US$1.9b
Last Updated
2020/01/19 00:44 UTC
Data Sources
Company Financials +
Executive Summary
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Invitae's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NVTA has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
17.4%
NVTA
0.9%
US Biotechs
2.0%
US Market
1 Year Return
31.4%
NVTA
11.3%
US Biotechs
23.6%
US Market
Return vs Industry: NVTA exceeded the US Biotechs industry which returned 10.9% over the past year.
Return vs Market: NVTA exceeded the US Market which returned 24.7% over the past year.
Shareholder returns
| NVTA | Industry | Market | |
|---|---|---|---|
| 7 Day | 17.4% | 0.9% | 2.0% |
| 30 Day | 20.2% | 0.7% | 3.9% |
| 90 Day | 10.7% | 20.6% | 12.0% |
| 1 Year | 31.4%31.4% | 12.3%11.3% | 26.2%23.6% |
| 3 Year | 130.7%130.7% | 28.9%24.6% | 53.2%43.3% |
| 5 Year | n/a | 4.3%-0.6% | 75.7%56.3% |
Price Volatility Vs. Market
How volatile is Invitae's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Rock star Growth Puts Invitae (NYSE:NVTA) In A Position To Use Debt1 month ago | Simply Wall St
Is Invitae Corporation's (NYSE:NVTA) CEO Paid Enough Relative To Peers?2 months ago | Simply Wall St
Here's What Analysts Are Forecasting For Invitae Corporation After Its Latest Third-Quarter ResultsValuation
Is Invitae undervalued compared to its fair value and its price relative to the market?
4.69x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NVTA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NVTA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NVTA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: NVTA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NVTA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NVTA is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Invitae forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
11.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NVTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NVTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NVTA's revenue (31.6% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: NVTA's revenue (31.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NVTA is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Invitae performed over the past 5 years?
-20.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NVTA is currently unprofitable.
Growing Profit Margin: NVTA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NVTA is unprofitable, and losses have increased over the past 5 years at a rate of -20.9% per year.
Accelerating Growth: Unable to compare NVTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: NVTA has a negative Return on Equity (-48.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Invitae's financial position?
Financial Position Analysis
Short Term Liabilities: NVTA's short term assets ($508.5M) exceed its short term liabilities ($68.9M).
Long Term Liabilities: NVTA's short term assets ($508.5M) exceed its long term liabilities ($317.6M).
Debt to Equity History and Analysis
Debt Level: NVTA's debt to equity ratio (65.7%) is considered high.
Reducing Debt: NVTA's debt to equity ratio has increased from 0% to 65.7% over the past 5 years.
Balance Sheet
Inventory Level: NVTA has a low level of unsold assets or inventory.
Debt Coverage by Assets: NVTA's debt is covered by short term assets (assets are 1.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVTA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NVTA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -9.9% each year
Next Steps
Dividend
What is Invitae's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate NVTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NVTA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NVTA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVTA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NVTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Invitae's salary, the management and board of directors tenure and is there insider trading?
3.0yrs
Average management tenure
CEO
Sean George (45yo)
3yrs
Tenure
US$2,233,360
Compensation
Dr. Sean E. George, Ph.D. is the Co-Founder of InVitae Corporation and has been its President since August 2012. Dr. George has been Chief Executive Officer of InVitae Corporation since January 9, 2017 and ...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD2.23M) is below average for companies of similar size in the US market ($USD3.86M).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.0yrs
Average Tenure
53.5yo
Average Age
Experienced Management: NVTA's management team is considered experienced (3 years average tenure).
Board Age and Tenure
4.2yrs
Average Tenure
54yo
Average Age
Experienced Board: NVTA's board of directors are considered experienced (4.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 5,000 |
| Max Price | US$25.68 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 20,447 |
| Max Price | US$25.29 |
| Entity | Individual |
| Role | Chief Operating Officer Secretary & COO |
| Shares | 21,265 |
| Max Price | US$25.29 |
| Entity | Individual |
| Role | Chief Executive Officer Co-Founder |
| Shares | 16,358 |
| Max Price | US$25.29 |
| Entity | Individual |
| Role | Senior Key Executive Chief Medical Officer |
| Shares | 20,447 |
| Max Price | US$25.29 |
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer |
| Shares | 22,900 |
| Max Price | US$25.29 |
| Entity | Individual |
| Role | Chief Legal Officer General Counsel |
| Shares | 13,663 |
| Max Price | US$25.29 |
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer |
| Shares | 6,474 |
| Max Price | US$18.21 |
| Entity | Individual |
| Role | Chief Legal Officer General Counsel |
| Shares | 2,146 |
| Max Price | US$18.21 |
| Entity | Individual |
| Role | Chief Operating Officer Secretary & COO |
| Shares | 6,851 |
| Max Price | US$18.21 |
| Entity | Individual |
| Role | Chief Executive Officer Co-Founder |
| Shares | 24,282 |
| Max Price | US$18.21 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 5,513 |
| Max Price | US$18.21 |
| Entity | Individual |
| Role | Senior Key Executive Chief Medical Officer |
| Shares | 7,202 |
| Max Price | US$18.21 |
| Entity | Individual |
| Role | Senior Key Executive Chief Commercial Officer |
| Shares | 1,000 |
| Max Price | US$25.23 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.9%.
Management Team
Lee Bendekgey (61yo)
Secretary & COO
- Tenure: 2.6yrs
- Compensation: US$1.48m
Robert Nussbaum (69yo)
Chief Medical Officer
- Tenure: 4.4yrs
- Compensation: US$802.74k
Shelly Guyer (59yo)
Chief Financial Officer
- Tenure: 2.6yrs
- Compensation: US$1.40m
Katherine Stueland (43yo)
Chief Commercial Officer
- Tenure: 3.3yrs
- Compensation: US$1.48m
Tom Brida (48yo)
General Counsel
- Tenure: 3yrs
Sean George (45yo)
Co-Founder
- Tenure: 3yrs
- Compensation: US$2.23m
Board Members
Eric Aguiar (57yo)
Independent Director
- Tenure: 9.3yrs
- Compensation: US$96.27k
Christine Gorjanc (62yo)
Independent Director
- Tenure: 4.2yrs
- Compensation: US$91.27k
Sean George (45yo)
Co-Founder
- Tenure: 3yrs
- Compensation: US$2.23m
Geoff Crouse (48yo)
Independent Director
- Tenure: 7.8yrs
- Compensation: US$96.27k
Chitra Nayak (54yo)
Independent Director
- Tenure: 1.3yrs
- Compensation: US$164.89k
Company Information
Invitae Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Invitae Corporation
- Ticker: NVTA
- Exchange: NYSE
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.895b
- Shares outstanding: 96.52m
- Website: https://www.invitae.com
Number of Employees
Location
- Invitae Corporation
- 1400 16th Street
- San Francisco
- California
- 94103
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NVTA | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Feb 2015 |
| IV8 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2015 |
| 0JDB | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Feb 2015 |
Biography
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California. Â
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/19 00:44 |
| End of Day Share Price | 2020/01/17 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.